ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

The Future of XMT-1536 in Ovarian Cancer and NSCLC

Don Bergstrom
Published Online:1:51 PM, Wed September 14, 2016

Don Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses the future of XMT-1536 in the treatment of ovarian cancer and non-small cell lung cancer (NSCLC).
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.